Reinfection · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse events and severe adverse events · people with chronic plaque psoriasis
1 finding from 1 review
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · people with chronic plaque psoriasis
It is very uncertain whether azithromycin changes proportion of participants achieving PASI 75 or PGA 1 to 2 compared with vitamin C (very low certainty).
1 finding from 1 review
Relapse · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microbiological cure · Pregnant women with a confirmed Chlamydia trachomatis infection
Azithromycin showed no clear difference in microbiological cure compared with erythromycin (moderate certainty).
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
It is very uncertain whether azithromycin changes participant‐assessed improvement in rosacea severity compared with doxycycline 100 mg (very low certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
It is very uncertain whether azithromycin changes proportion of participants with adverse event compared with doxycycline 100 mg (very low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission · Participants with rosacea
1 finding from 1 review
Stool volume · Adults and children with cholera diarrhoea
1 finding from 1 review
Bacteriological failure · Adults and children with cholera diarrhoea
Azithromycin showed no clear difference in bacteriological failure compared with erythromycin (low certainty).
1 finding from 1 review
Duration of diarrhoea · Adults and children with cholera diarrhoea
1 finding from 1 review
Stool volume · Adults and children with cholera diarrhoea
1 finding from 1 review
Bacteriological failure · Adults and children with cholera diarrhoea
Azithromycin may leads to lower bacteriological failure compared with ciprofloxacin (low certainty).
1 finding from 1 review